.. First ovarian cancer therapy for ST oncology portfolio .. Phase 2 study demonstrated oregovomab ...
* SEA's largest independent specialty pharma company Specialised Therapeutics (ST) has joined glo...
.. ST to partner with Dutch biotech company Treeway BV .. First CNS therapy in ST therapeutic portf...
* YONDELIS® (trabectedin) now PBS listed for Australian patients * Listing described as "wonderf...
MINJUVI® (tafasitamab) provisionally approved by Therapeutic Goods Administration[1] Recent five-y...
* Singapore's Health Sciences Authority (HSA) has approved QINLOCK® (ripretinib) for the treatmen...
SINGAPORE, April 11, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therape...
* Globally regarded soft-tissue sarcoma therapy has been approved by Medsafe forNew Zealand patie...
* QINLOCK® (ripretinib) now Medsafe approved for GIST patients in NZ * QINLOCK now being conside...
* Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 ...
* NERLYNX® (neratinib) is approved by the Food and Drug Administration of the Philippines * Le...
SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeut...
Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved in Singapore to treat ...
Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved to treat second-li...
Key Highlights: * Specialised Therapeutics Asia (STA) to make QINLOCK® (ripretinib) available to...
SINGAPORE, July 16, 2020 /PRNewswire/ -- A NEW breast cancer drug shown to significantly reduce the...
Key Highlights * TGA has granted provisional designation for new drug Lurbinectedin based on enc...
* NERLYNX® (neratinib) now commercially available in Singapore for HER2+ breast cancer patients f...